James Gavin III, MD, PhD

James Gavin III, MD, PhD


Clinical Professor of Medicine
Emory University School of Medicine  Atlanta, Georgia
Clinical Professor of Medicine
Indiana University School of Medicine  Indianapolis, IN, USA

Related Videos

The Intersection of Trial Data and Real World Evidence for the Application of Sensor-Based Glucose Monitoring Technology for the Diabetes and Primary Care Specialist Video

The Intersection of Trial Data and Real World Evidence for the Application of Sensor-Based Glucose Monitoring Technology for the Diabetes and Primary Care Specialist

Optimizing Multiple Glycemic/Metabolic Control and Patient Safety Metrics in the Covid-19 Era and Beyond

How Have Recent Studies Helped Us Identify Persons with Diabetes Who Are Ideal Candidates for Sensor-Based CGM? Video

How Have Recent Studies Helped Us Identify Persons with Diabetes Who Are Ideal Candidates for Sensor-Based CGM?

Who Benefits? In What Way? Using What Methods?

Case-Based, Real World Applications of Sensor-Based CGM to the Front Lines of Diabetes Care Video

Case-Based, Real World Applications of Sensor-Based CGM to the Front Lines of Diabetes Care

The Faculty Discuss, Analyze, and Provide Expert-Based Consultation for How to Interpret AGP Reports and Make Therapeutic Decisions in Persons with Type 2 and Type 1 Diabetes

Interactive Q&A Session Video

Interactive Q&A Session

The Evolving Landscape of Sensor-Based Technology for Optimizing Clinical Outcomes Across the Comprehensive Spectrum of Type 2 and Type 1 Diabetes Care Video

The Evolving Landscape of Sensor-Based Technology for Optimizing Clinical Outcomes Across the Comprehensive Spectrum of Type 2 and Type 1 Diabetes Care

The Foundational Role of Sensor-Based Glucose Monitoring Technology Video

The Foundational Role of Sensor-Based Glucose Monitoring Technology

A Data-Driven Rationale for the Early Deployment of Continuous Glucose Monitoring (CGM)<br><sub>Late-Breaking Trials and Guidance for Initial Interventions in Type 2 Diabetes </sub> Video

A Data-Driven Rationale for the Early Deployment of Continuous Glucose Monitoring (CGM)
Late-Breaking Trials and Guidance for Initial Interventions in Type 2 Diabetes